# Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

Study · id `cardio:ct-nct04603508` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04603508](<https://clinicaltrials.gov/study/NCT04603508>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04603508

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT04603508. Randomized; double masking; primary purpose treatment. Start 2023-03 (anticipated); primary completion 2025-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT04603508, source copy `cardio:ctgov-nct04603508-2022-08-05`, retrieved 2026-10-26)
- Planned start: 2023-03 (anticipated) (ClinicalTrials.gov record NCT04603508, source copy `cardio:ctgov-nct04603508-2022-08-05`, retrieved 2026-10-26)
- Primary completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT04603508, source copy `cardio:ctgov-nct04603508-2022-08-05`, retrieved 2026-10-26)
- Completion: 2025-08 (anticipated) (ClinicalTrials.gov record NCT04603508, source copy `cardio:ctgov-nct04603508-2022-08-05`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04603508-2022-08-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
- Condition: Type 2 Diabetes Mellitus
- Condition: Dyslipidemia
- Intervention (Drug): BERLIM 25/10 association
- Intervention (Drug): EMPAGLIFLOZIN
- Intervention (Drug): ROSUVASTATIN CALCIUM
- Intervention (Other): BERLIM 25/10 ASSOCIATION PLACEBO
- Intervention (Other): EMPAGLIFLOZIN PLACEBO
- Intervention (Other): ROSUVASTATIN CALCIUM PLACEBO
- Lead sponsor: EMS
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)

## Provenance

Content hash: 8236cb1530655dfa1bb7cc4068a5f5a6a5282fc620b119f1315ea8b0c66ed681
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
